AR082160A1 - Anticuerpos monoclonales dirigidos contra la toxina tetanica - Google Patents

Anticuerpos monoclonales dirigidos contra la toxina tetanica

Info

Publication number
AR082160A1
AR082160A1 ARP110102508A ARP110102508A AR082160A1 AR 082160 A1 AR082160 A1 AR 082160A1 AR P110102508 A ARP110102508 A AR P110102508A AR P110102508 A ARP110102508 A AR P110102508A AR 082160 A1 AR082160 A1 AR 082160A1
Authority
AR
Argentina
Prior art keywords
directed against
toxin
monoclonal antibodies
antibodies directed
amino acid
Prior art date
Application number
ARP110102508A
Other languages
English (en)
Spanish (es)
Inventor
Sylvie Jorieux
Romeuf Christophe De
Original Assignee
Lfb Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lfb Biotechnologies filed Critical Lfb Biotechnologies
Publication of AR082160A1 publication Critical patent/AR082160A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP110102508A 2010-07-12 2011-07-12 Anticuerpos monoclonales dirigidos contra la toxina tetanica AR082160A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1055671A FR2962439A1 (fr) 2010-07-12 2010-07-12 Anticorps monoclonaux diriges contre la toxine tetanique

Publications (1)

Publication Number Publication Date
AR082160A1 true AR082160A1 (es) 2012-11-14

Family

ID=43732782

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102508A AR082160A1 (es) 2010-07-12 2011-07-12 Anticuerpos monoclonales dirigidos contra la toxina tetanica

Country Status (3)

Country Link
AR (1) AR082160A1 (fr)
FR (1) FR2962439A1 (fr)
WO (1) WO2012007688A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018078643A1 (fr) * 2016-10-26 2018-05-03 Bharat Serums And Vaccines Ltd. Anticorps monoclonaux neutralisant la toxine tétanique
CN111239384A (zh) * 2020-01-15 2020-06-05 中国人民解放军陆军军医大学 一种破伤风毒素检测试剂盒
EP4271409A1 (fr) * 2020-12-30 2023-11-08 ISAR Bioscience GmbH Antigènes et dosages pour la détection d'anticorps contre le sars-cov-2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE166924T1 (de) 1992-03-23 1998-06-15 Schweiz Serum & Impfinst Monoklonale antikörper gegen tetanustoxin und sie enthaltende pharmazeutische zusammensetzungen
US7700738B2 (en) * 2005-01-27 2010-04-20 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins

Also Published As

Publication number Publication date
FR2962439A1 (fr) 2012-01-13
WO2012007688A1 (fr) 2012-01-19

Similar Documents

Publication Publication Date Title
MX360741B (es) Constructos de polipéptidos y sus usos.
NZ602220A (en) Antibodies with ph dependent antigen binding
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
MX2015014608A (es) Novedosas moleculas de union biespecifica con actividad antitumoral.
BR112015004022A2 (pt) aminoácidos modificados compreendendo um grupo azido
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX2021007006A (es) Anticuerpo anti-calicreina-2 humanizado.
MX357972B (es) Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
TR201808046T4 (tr) İki veya daha fazla sayıda antijen molekülüne tekrar tekrar bağlanabilen antijen bağlanma molekülü.
CY1119916T1 (el) Ανοσογονικη συνθεση
MX2014005546A (es) Anticuerpos de union de albumina y fragmentos de union de los mismos.
UA106607C2 (uk) Білки специфічного зв'язування і їх застосування
NZ594682A (en) Fully human antibodies specific to cadm1
TR201815254T4 (tr) Tl1a'ya bağlanan anti̇korlar ve bunlarin kullanimlari
NZ595792A (en) Antibodies specific to cadherin-17
MX2016004579A (es) Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
NZ598770A (en) Monoclonal antibodies
EA201291065A1 (ru) Антитела против vla-4
NZ610091A (en) Antibodies
GB201118394D0 (en) Vaccine
AR082160A1 (es) Anticuerpos monoclonales dirigidos contra la toxina tetanica
GB0611708D0 (en) Novel antibodies against prion protein and uses thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure